secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2024-10-11T23:59:59+00:00
Accession:  0001437749-24-031059
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity regains Nasdaq minimum bid price compliance after 20-day period
------------------------------------------------------------------------

- Received Nasdaq notice on Oct 9, 2024 confirming compliance with Listing Rule 5550(a)(2).
- Stock closing bid price was $1.00 or greater for 20 consecutive days from Sept 11 to Oct 9, 2024.
- Non-compliance was first notified on June 18, 2024; this matter is now closed.
- CEO Thomas Jensen stated focus remains on stenoparib Phase 2 trial in advanced ovarian cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000143774924031059/0001437749-24-031059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000143774924031059/allr20241010_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-031059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer